Modality
siRNA
MOA
BETi
Target
MDM2
Pathway
Sphingolipid
DravetFSGS
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
→ Apr 2021
Phase 1Current
NCT04118402
530 pts·FSGS
2021-04→TBD·Active
NCT03368149
921 pts·Dravet
2020-06→TBD·Active
1,451 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q3Q42021Q2
P1/2
Active
P1/2
Active
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04118402 | Phase 1/2 | FSGS | Active | 530 | CfB |
| NCT03368149 | Phase 1/2 | Dravet | Active | 921 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| BII-1564 | Biogen | Phase 2 | PSMA |